Glycophos (Sodium Glycerophosphate Pentahydrate)

Glycophos is administered intravenously when a rapid increase in serum phosphate levels is clinically indicated, particularly in hospital environments such as intensive care units or during major surgical procedures.

• Treatment of documented hypophosphatemia to restore normal phosphate concentrations.
• Supplementation of phosphate in patients receiving continuous renal replacement therapy who are at risk of depletion.
• Inclusion in parenteral nutrition regimens to provide essential phosphate for metabolic processes.
• Management of refeeding syndrome where rapid phosphate shifts can occur after nutritional rehabilitation.
• Correction of electrolyte imbalances during major surgery or trauma care when phosphate loss is anticipated.

Intravenous administration of sodium glycerophosphate may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common

• Mild elevation of serum phosphate that typically resolves without additional treatment.
• Transient decrease in calcium levels, which may cause mild tingling or paresthesia.
• Nausea or mild gastrointestinal discomfort such as stomach upset.
• Local irritation, erythema, or pain at the infusion site during or after administration.

Serious

• Marked hyperphosphatemia that can lead to calcium‑phosphate precipitation and tissue calcification.
• Metabolic acidosis resulting from an excessive phosphate load, potentially requiring corrective measures.
• Severe hypersensitivity reactions, including rash, bronchospasm, or anaphylaxis, necessitating immediate medical intervention.

When using Glycophos, clinicians should observe specific precautions to minimize risks and ensure safe administration.

• Verify baseline serum phosphate and calcium concentrations before initiating therapy.
• Continuously monitor electrolyte levels, especially phosphate, calcium, and magnesium, throughout the infusion.
• Reduce or adjust the dose in patients with impaired renal function or severe kidney disease.
• Infuse the solution at the recommended rate to prevent sudden shifts in phosphate balance.
• Ensure compatibility with other intravenous medications and avoid mixing in the same line unless stability is confirmed.
• Follow strict aseptic technique during preparation and administration to prevent infection.

Sodium glycerophosphate may interact with certain medications or clinical conditions; awareness of these interactions helps guide safe co‑administration.

Avoid

• Concurrent infusion of calcium salts or calcium‑containing solutions, which can precipitate calcium‑phosphate crystals.
• Administration together with other phosphate‑rich intravenous fluids, increasing risk of hyperphosphatemia.
• Use in patients with untreated severe hyperphosphatemia, as it may exacerbate the condition.

Use with caution

• Co‑administration with loop or thiazide diuretics that alter calcium and phosphate balance; monitor electrolytes closely.
• Concurrent use of vitamin D analogues or calcitriol, which can affect calcium‑phosphate homeostasis.
• Patients receiving anticoagulant therapy, particularly warfarin, may require monitoring of calcium‑dependent clotting factors.